<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jah310366" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39604021</article-id><article-id pub-id-type="pmc">PMC11681592</article-id>
<article-id pub-id-type="doi">10.1161/JAHA.124.036761</article-id><article-id pub-id-type="publisher-id">JAH310366</article-id><article-id pub-id-type="other">JAHA/2024/036761-T</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Stroke</subject></subj-group></subj-group></article-categories><title-group><article-title>Risk Factors, Treatments, and Outcomes of Adults Aged &#x0003c;55&#x02009;Years With Acute Ischemic Stroke With Undetermined Versus Determined Pathogenesis: A Nationwide Swiss Cohort Study</article-title><alt-title alt-title-type="right-running-head">Acute Ischemic Stroke in Young Adults</alt-title><alt-title alt-title-type="left-running-head">Dittrich et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah310366-cr-0001" contrib-type="author" corresp="yes"><name><surname>Dittrich</surname><given-names>Tolga D.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9987-3631</contrib-id><xref rid="jah310366-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310366-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="jah310366-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref><address><email>tolga.dittrich@kssg.ch</email></address></contrib><contrib id="jah310366-cr-0002" contrib-type="author"><name><surname>Schneider</surname><given-names>Thomas</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310366-note-0001" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib id="jah310366-cr-0003" contrib-type="author"><name><surname>Katan</surname><given-names>Mira</given-names></name><degrees>MD, MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9265-8066</contrib-id><xref rid="jah310366-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jah310366-cr-0004" contrib-type="author"><name><surname>Luft</surname><given-names>Andreas R.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9865-7382</contrib-id><xref rid="jah310366-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jah310366-cr-0005" contrib-type="author"><name><surname>Mono</surname><given-names>Marie&#x02010;Luise</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4886-0010</contrib-id><xref rid="jah310366-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jah310366-cr-0006" contrib-type="author"><name><surname>Bolognese</surname><given-names>Manuel</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4757-2834</contrib-id><xref rid="jah310366-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="jah310366-cr-0007" contrib-type="author"><name><surname>Nedeltchev</surname><given-names>Krassen</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7614-1227</contrib-id><xref rid="jah310366-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="jah310366-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jah310366-cr-0008" contrib-type="author"><name><surname>Kahles</surname><given-names>Timo</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1569-6376</contrib-id><xref rid="jah310366-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="jah310366-cr-0009" contrib-type="author"><name><surname>Arnold</surname><given-names>Marcel</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4274-4644</contrib-id><xref rid="jah310366-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jah310366-cr-0010" contrib-type="author"><name><surname>Heldner</surname><given-names>Mirjam</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3594-2159</contrib-id><xref rid="jah310366-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jah310366-cr-0011" contrib-type="author"><name><surname>Michel</surname><given-names>Patrik</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4954-7579</contrib-id><xref rid="jah310366-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="jah310366-cr-0012" contrib-type="author"><name><surname>Carrera</surname><given-names>Emmanuel</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0045-5382</contrib-id><xref rid="jah310366-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="jah310366-cr-0013" contrib-type="author"><name><surname>Rodic</surname><given-names>Biljana</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="jah310366-cr-0014" contrib-type="author"><name><surname>Cereda</surname><given-names>Carlo W.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6479-1476</contrib-id><xref rid="jah310366-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="jah310366-cr-0015" contrib-type="author"><name><surname>Peters</surname><given-names>Nils</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8451-7389</contrib-id><xref rid="jah310366-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="jah310366-cr-0016" contrib-type="author"><name><surname>Bonati</surname><given-names>Leo H.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1163-8133</contrib-id><xref rid="jah310366-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="jah310366-cr-0017" contrib-type="author"><name><surname>Renaud</surname><given-names>Susanne</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="jah310366-cr-0018" contrib-type="author"><name><surname>Humm</surname><given-names>Andrea M.</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="jah310366-cr-0019" contrib-type="author"><name><surname>Medlin</surname><given-names>Friedrich</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8477-899X</contrib-id><xref rid="jah310366-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="jah310366-cr-0020" contrib-type="author"><name><surname>Albert</surname><given-names>Sylvan</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="jah310366-cr-0021" contrib-type="author"><name><surname>Sturzenegger</surname><given-names>Rolf</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3665-069X</contrib-id><xref rid="jah310366-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="jah310366-cr-0022" contrib-type="author"><name><surname>Tarnutzer</surname><given-names>Alexander A.</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6984-6958</contrib-id><xref rid="jah310366-aff-0018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib id="jah310366-cr-0023" contrib-type="author"><name><surname>Siebel</surname><given-names>Philip</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib id="jah310366-cr-0024" contrib-type="author"><name><surname>Baumg&#x000e4;rtner</surname><given-names>Markus</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0020" ref-type="aff">
<sup>20</sup>
</xref></contrib><contrib id="jah310366-cr-0025" contrib-type="author"><name><surname>Berger</surname><given-names>Christian</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0021" ref-type="aff">
<sup>21</sup>
</xref></contrib><contrib id="jah310366-cr-0026" contrib-type="author"><name><surname>Mordasini</surname><given-names>Pasquale</given-names></name><degrees>MD</degrees><xref rid="jah310366-aff-0022" ref-type="aff">
<sup>22</sup>
</xref></contrib><contrib id="jah310366-cr-0027" contrib-type="author"><name><surname>Vehoff</surname><given-names>Jochen</given-names></name><degrees>MD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9531-8262</contrib-id><xref rid="jah310366-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jah310366-cr-0028" contrib-type="author"><name><surname>De Marchis</surname><given-names>Gian Marco</given-names></name><degrees>MD, MSc</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0342-9780</contrib-id><xref rid="jah310366-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jah310366-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jah310366-cr-0029" contrib-type="author"><collab collab-type="authors">the Swiss Stroke Registry Investigators</collab><xref rid="jah310366-note-0002" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref></contrib></contrib-group><aff id="jah310366-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Teaching and Research Hospital St. Gallen</institution>
<city>St. Gallen</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Research</named-content>
<institution>University of Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital Basel and University of Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital Zurich</institution>
<city>Zurich</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Municipal Hospital Waid und Triemli</institution>
<city>Zurich</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital of Lucerne</institution>
<city>Lucerne</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Aarau</institution>
<city>Aarau</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital Bern and University of Bern</institution>
<city>Bern</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital Lausanne</institution>
<city>Lausanne</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University Hospital Geneva</institution>
<city>Geneva</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Winterthur</institution>
<city>Winterthur</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>EOC Neurocenter of Southern Switzerland</institution>
<city>Lugano</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Hirslanden Hospital Zurich</institution>
<city>Zurich</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Neurorehabilitation</named-content>
<institution>Rheinfelden Rehabilitation Clinic</institution>
<city>Rheinfelden</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Neuch&#x000e2;tel</institution>
<city>Neuch&#x000e2;tel</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Department of Internal Medicine, Neurological Unit</named-content>
<institution>HFR Fribourg &#x02013; Cantonal Hospital</institution>
<city>Fribourg</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Graub&#x000fc;nden</institution>
<city>Chur</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0018">
<label>
<sup>18</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital of Baden</institution>
<city>Baden</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0019">
<label>
<sup>19</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Frauenfeld</institution>
<city>Frauenfeld</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0020">
<label>
<sup>20</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital M&#x000fc;nsterlingen</institution>
<city>M&#x000fc;nsterlingen</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0021">
<label>
<sup>21</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Cantonal Hospital Grabs</institution>
<city>Grabs</city>
<country country="CH">Switzerland</country>
</aff><aff id="jah310366-aff-0022">
<label>
<sup>22</sup>
</label>
<named-content content-type="organisation-division">Department of Neuroradiology</named-content>
<institution>Cantonal Hospital Aarau</institution>
<city>Aarau</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
Correspondence to: Tolga D. Dittrich, MD, PhD, Department of Neurology, University Teaching and Research Hospital , l St. Gallen, Rorschacher Str. 95, CH&#x02010;9007 St. Gallen, Switzerland. Email: <email>tolga.dittrich@kssg.ch</email>
<break/>
</corresp><fn fn-type="equal" id="jah310366-note-0001"><label>*</label><p>Tolga D. Dittrich and Thomas Schneider contributed equally to this article.</p></fn><fn id="jah310366-note-0002"><label>&#x02020;</label><p>A complete list of the Swiss Stroke Registry Investigators can be found in the Supplemental Material.</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><day>03</day><month>12</month><year>2024</year></pub-date><volume>13</volume><issue seq="390">23</issue><issue-id pub-id-type="doi">10.1002/jah3.v13.23</issue-id><elocation-id>e036761</elocation-id><history>
<date date-type="received"><day>08</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>18</day><month>10</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JAH3-13-e036761.pdf"/><abstract><sec id="jah310366-sec-0001"><title>Background</title><p>The rising prevalence of acute ischemic stroke (AIS) in young adults, particularly with undetermined pathogenesis, is a growing concern. This study assessed risk factors, treatments, and outcomes between young AIS patients with undetermined and determined pathogeneses.</p></sec><sec id="jah310366-sec-0002"><title>Methods and Results</title><p>This was a retrospective cohort study including AIS patients aged 18 to 55&#x02009;years in Switzerland, treated between 2014 and 2022. Stroke pathogeneses were classified using a modified TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, with undetermined pathogenesis defined as no identified cause (including patent foramen ovale and cervical artery dissection). We examined vascular risk factors, acute treatments, 3&#x02010;month functional outcomes, and AIS recurrence within 3 months using logistic regression and Fine&#x02013;Gray proportional hazards models. Of 3995 patients, 863 (22%) had undetermined pathogenesis. Compared with patients with determined pathogenesis, those with undetermined pathogenesis had a higher prevalence of dyslipidemia (54% versus 59%, <italic toggle="no">P</italic>=0.007) and smoking (37% versus 43%, <italic toggle="no">P</italic>=0.001), and were more likely to receive intravenous thrombolysis (27% versus 31%, <italic toggle="no">P</italic>=0.046). Despite higher 3&#x02010;month AIS recurrence risk for the undetermined group (adjusted hazard ratio, 1.72 [95% CI, 1.01&#x02013;2.94]), favorable functional outcomes at 3 months were more frequent (modified Rankin Scale score, 0&#x02013;2: 90% versus 87%, <italic toggle="no">P</italic>=0.033). Patients aged 46 to 55&#x02009;years with undetermined pathogenesis had better outcomes than those with determined pathogenesis (modified Rankin Scale score, 0&#x02013;1: 70% versus 64%, <italic toggle="no">P</italic>=0.013; modified Rankin Scale score, 0&#x02013;2: 89% versus 85%, <italic toggle="no">P</italic>=0.023), while those aged 18 to 45&#x02009;years showed higher recurrence rates (4.5% versus 1.8%, <italic toggle="no">P</italic>&#x0003c;0.05) but similar functional outcomes.</p></sec><sec id="jah310366-sec-0003"><title>Conclusions</title><p>Young adults with AIS exhibit a considerable vascular risk burden. Those with undetermined pathogenesis displayed age&#x02010;related outcome disparities, with better short&#x02010;term outcomes in older and higher recurrence rates in younger patients.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah310366-kwd-0001">ischemic stroke</kwd><kwd id="jah310366-kwd-0002">undetermined pathogenesis</kwd><kwd id="jah310366-kwd-0003">vascular risk factors</kwd><kwd id="jah310366-kwd-0004">young</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Cerebrovascular Disease/Stroke</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="13"/><word-count count="7200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>03 December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:03.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jah310366-ntgp-0001"><fn id="jah310366-note-0003"><p>This manuscript was sent to Daniel T. Eitzman, MD, Senior Guest Editor, for review by expert referees, editorial decision, and final disposition.</p></fn><fn id="jah310366-note-0004"><p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.036761" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.036761</ext-link>
</p></fn><fn id="jah310366-note-0005"><p>For Sources of Funding and Disclosures, see page 13.</p></fn></fn-group></notes></front><body id="jah310366-body-0001"><def-list list-content="abbreviations" id="jah310366-dl-0001"><title>Nonstandard Abbreviations and Acronyms</title><def-item><term id="jah310366-li-0001">AIS</term><def id="jah310366-li-0002"><p>acute ischemic stroke</p></def></def-item><def-item><term id="jah310366-li-0003">IAT</term><def id="jah310366-li-0004"><p>intra&#x02010;arterial treatment</p></def></def-item><def-item><term id="jah310366-li-0005">IVT</term><def id="jah310366-li-0006"><p>intravenous thrombolysis</p></def></def-item><def-item><term id="jah310366-li-0007">mRS</term><def id="jah310366-li-0008"><p>modified Rankin Scale</p></def></def-item><def-item><term id="jah310366-li-0009">NAVIGATE ESUS</term><def id="jah310366-li-0010"><p>New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source</p></def></def-item><def-item><term id="jah310366-li-0011">PFO</term><def id="jah310366-li-0012"><p>patent foramen ovale</p></def></def-item><def-item><term id="jah310366-li-0013">RE&#x02010;SPECT ESUS</term><def id="jah310366-li-0014"><p>Randomized, Double&#x02010;Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source</p></def></def-item><def-item><term id="jah310366-li-0015">SSR</term><def id="jah310366-li-0016"><p>Swiss Stroke Registry</p></def></def-item><def-item><term id="jah310366-li-0017">SYSS</term><def id="jah310366-li-0018"><p>Swiss Young Stroke Study</p></def></def-item><def-item><term id="jah310366-li-0019">TOAST</term><def id="jah310366-li-0020"><p>Trial of ORG 10172 in Acute Stroke Treatment</p></def></def-item></def-list><p>
<boxed-text position="anchor" content-type="box" id="jah310366-blkfxd-0001"><caption><title>Clinical Perspective</title></caption><sec id="jah310366-sec-0006"><title>What Is New?</title><p>
<list list-type="bullet" id="jah310366-list-0001"><list-item id="jah310366-li-0021"><p>Young adults with acute ischemic stroke of undetermined pathogenesis have a high vascular risk burden, with elevated recurrence risk particularly in those aged 18 to 45&#x02009;years, but show better functional outcomes, especially in those aged 46 to 55&#x02009;years.</p></list-item></list>
</p></sec><sec id="jah310366-sec-0007"><title>What Are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah310366-list-0002"><list-item id="jah310366-li-0022"><p>Improved targeted secondary prevention strategies are needed, particularly for young patients with AIS with undetermined pathogenesis aged &#x0003c;45&#x02009;years, to address their elevated recurrence risk.</p></list-item></list>
</p></sec></boxed-text>
</p><p>Stroke in young adults not only represents a growing concern due to its increasing incidence but also poses substantial socioeconomic implications, affecting individuals in their most productive years.<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Recent studies indicate that 10% to 15% of strokes occur in individuals aged &#x0003c;50&#x02009;years, a demographic not traditionally considered at high stroke risk.<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Despite a general decline in stroke prevalence in high&#x02010;income countries, stroke incidence is rising among younger populations.<xref rid="jah310366-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jah310366-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>This trend has public health significance, considering the impact of stroke on the quality of life of young patients and their caregivers.<xref rid="jah310366-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jah310366-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Approximately one third of young stroke survivors experience disabilities impacting daily activities and work participation,<xref rid="jah310366-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jah310366-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> with a 20&#x02010;year mortality rate of 26.8%, highlighting the urgent need for dedicated research focused on the management of modifiable vascular risk factors and pathogenesis&#x02010;tailored secondary prevention strategies.<xref rid="jah310366-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>The observed increase in stroke incidence among young adults is partially attributed to an increasing prevalence of traditional vascular risk factors, such as smoking, hypertension, and dyslipidemia.<xref rid="jah310366-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> While diabetes, hypertension, and obesity are prevalent and often undertreated in patients aged &#x0003c;55&#x02009;years with stroke,<xref rid="jah310366-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> these factors alone do not fully account for the rising stroke incidence in this age group, especially given the declining rates of myocardial infarction among the young. Recent studies indicate a rising number of ischemic cerebrovascular events among patients aged &#x0003c;55&#x02009;years without established vascular risk factors, particularly in cryptogenic cases.<xref rid="jah310366-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Research on young adults (aged 18&#x02013;49&#x02009;years) with first&#x02010;ever acute ischemic stroke (AIS) revealed that traditional vascular risk factors are less prevalent in cryptogenic AIS than in cases with determined pathogenesis,<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> suggesting a unique risk profile for this group. The difference in prognosis between determined and undetermined stroke pathogenesis cases, particularly in terms of functional outcome and recurrence rates in young patients, remains unclear. One study reported a higher functional independence rate at 3 months in patients with undetermined pathogenesis compared with those with a determined pathogenesis, without stratification by age group (79.7% versus 73.1%).<xref rid="jah310366-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>In a Swiss cohort of young adults aged 18&#x02013;55&#x02009;years with AIS, we aimed to provide a description of the (1) prevalence of vascular risk factors, (2) acute treatments, (3) 3&#x02010;month functional outcomes, and (4) stroke recurrence risk and compare these aspects between patients with undetermined and determined pathogenesis.</p><sec sec-type="methods" id="jah310366-sec-0008"><title>Methods</title><sec id="jah310366-sec-0009"><title>Protocol Approval, Registration, and Data Availability</title><p>In accordance with Swiss legislation, enrollment in the SSR (Swiss Stroke Registry) is mandated for quality assurance measures. Patients are notified about the potential use for research with the provision that individuals who dissent to the use of their data are excluded from research projects. This study has received prior approval from the Ethics Committee Northwestern Switzerland (ID 2023&#x02013;01248). Anonymized data and statistical code are available upon request.</p></sec><sec id="jah310366-sec-0010"><title>Study Design and Participants</title><p>This retrospective multicenter study used data from the SSR, a national, prospective registry designed for quality assurance and multicentric research in acute stroke care.</p><p>We included all consecutive patients aged 18&#x02013;55&#x02009;years with first&#x02010;ever, imaging&#x02010;confirmed AIS (ie, diffusion restriction on magnetic resonance imaging or arterial occlusion on computed tomography or magnetic resonance angiography or perfusion deficit on computed tomography/magnetic resonance perfusion imaging) treated at a certified Swiss stroke center or unit between January 2014 and September 2022. We excluded patients with incomplete diagnostic workup (defined as requiring at a minimum: extra&#x02010; and intracranial assessment of cerebral arteries, ECG, and evaluation by a trained cardiologist), stroke mimics and those who declined research use of their data.</p><p>A detailed list of all baseline and follow&#x02010;up variables extracted from the SSR is provided in Data&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="jah310366-sec-0011"><title>Stroke Pathogenesis</title><p>The SSR uses a modified version of the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification, categorizing AIS into 5 distinct categories: large&#x02010;artery atherosclerosis (&#x02265;50% stenosis), cardioembolic (excluding patent foramen ovale [PFO] or other rare cardiac sources), small&#x02010;vessel disease, stroke of other determined pathogenesis, and stroke of undetermined pathogenesis (despite complete diagnostic workup). In addition to these TOAST categories, the SSR captures specific causes like carotid artery dissection, PFO as the sole cause (with &#x0003c;3 vascular risk factors), and cases with &#x0003e;1 possible pathogenesis.</p><p>Further measures to improve data integrity are described in Data&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="jah310366-sec-0012"><title>Vascular Risk Factors and Manifest Vascular Disease</title><p>The SSR documents the following established vascular risk factors: arterial hypertension (defined as blood pressure &#x0003e;140/90&#x02009;mm&#x000a0;Hg or a history of hypertension), hyperlipidemia (indicated by lipid&#x02010;lowering therapy on admission or low&#x02010;density lipoprotein cholesterol &#x0003e;2.6&#x02009;mmol/L), diabetes (excluding glucose intolerance), smoking (actively smoking or stopped &#x0003c;2&#x02009;years ago), and body mass index upon admission. Additionally, it captures histories of transient ischemic attack, intracranial hemorrhage, coronary artery disease, presence of prosthetic heart valves, and low cardiac ejection fraction (&#x0003c;35%).</p></sec><sec id="jah310366-sec-0013"><title>Acute Treatment and Time Metrics</title><p>The following acute treatment&#x02013;related information is recorded in the SSR: antiplatelet therapy (either single or dual), anticoagulants (oral or parenteral at therapeutic doses), intravenous thrombolysis (IVT) with recombinant tissue&#x02010;type plasminogen activator, onset&#x02010;to&#x02010;IVT time, door&#x02010;to&#x02010;IVT time, intra&#x02010;arterial treatment (IAT), onset&#x02010;to&#x02010;IAT time, and door&#x02010;to&#x02010;IAT time.</p></sec><sec id="jah310366-sec-0014"><title>Functional Outcome and Stroke Recurrence</title><p>Functional outcome measures recorded in the SSR include the modified Rankin Scale (mRS) score at 3 months. Method of follow&#x02010;up (ranging from in&#x02010;person clinic visits and telephone interviews to medical record reviews) is chosen by each SSR participating center. Recurrent strokes and deaths are systematically captured throughout the 3&#x02010;month follow&#x02010;up period.</p></sec><sec id="jah310366-sec-0015"><title>Outcome Measures</title><p>Outcome measures were the prevalence of traditional vascular risk factors (arterial hypertension, diabetes, dyslipidemia, smoking), the proportion receiving acute treatments (IVT, IAT, antiplatelet treatment, and therapeutic anticoagulation), functional outcome at 3 months measured by the mRS score (ordinal and dichotomized [0&#x02013;1 versus 2&#x02013;6; 0&#x02013;2 versus 3&#x02013;6]; with mRS scores of 0&#x02013;1 indicating excellent, and 0&#x02013;2 favorable outcome), and AIS recurrence within 3 months.</p></sec><sec id="jah310366-sec-0016"><title>Statistical Analysis</title><p>Statistical analyses compared patients with undetermined stroke pathogenesis and (1) those with determined pathogeneses on the basis of the modified TOAST classification (large&#x02010;artery atherosclerosis, cardioembolic, small&#x02010;vessel occlusion, stroke of other determined pathogenesis, carotid artery dissection, PFO, &#x0003e;1 possible pathogenesis), and (2) an aggregated group including all patients with determined stroke pathogenesis. Additionally, we compared patients with undetermined pathogenesis to those with determined pathogenesis within the age subgroups of 18 to 45 and 46 to 55&#x02009;years.</p><p>Categorical variables are presented as counts with percentages, and continuous variables as medians with interquartile ranges (IQRs). The Kruskal&#x02013;Wallis rank&#x02010;sum test (continuous variables) and Pearson &#x003c7;<sup>2</sup> test (categorical variables) were used to assess group differences.</p><p>We fitted logistic regression models to predict good (mRS score, 0&#x02013;2 versus 3&#x02013;6) and excellent functional outcomes (mRS score, 0&#x02013;1 versus 2&#x02013;6) at 3 months follow&#x02010;up using maximum likelihood estimation. To assess whether an undetermined stroke pathogenesis independently affects functional outcome, we fitted models that included age, sex, pathogenesis (determined versus undetermined), and interactions between age and pathogenesis, and sex and pathogenesis. Sensitivity analyses involved fitting separate models for age subgroups (18&#x02013;45 and 46&#x02013;55&#x02009;years). Additionally, we fitted models using the modified TOAST stroke pathogenesis (as a factor) with undetermined pathogenesis as the reference, controlling for age (centered at the grand population mean) and sex (female as reference).</p><p>Fine&#x02013;Gray proportional hazards models, adjusted for age and sex, evaluated the impact of undetermined (versus determined) stroke pathogenesis on stroke recurrence within 3 months, considering death as a competing risk.<xref rid="jah310366-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Event of recurrent stroke and death were censored at 3 months for cumulative incidence and proportional hazards analyses. Analyses were limited to cases with complete covariable sets, and model terms were assessed using the Wald test. This analysis was conducted for the total data set as well as for the age subgroups 18 to 45 and 46 to 55&#x02009;years.</p><p>Missing values were discarded from analyses. The number of observations is given for all variables and models in the Table&#x000a0;<xref rid="jah310366-tbl-0001" ref-type="table">1</xref> and Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S1</xref>, respectively. <italic toggle="yes">P</italic> values &#x0003c;0.05 were considered significant, and we report 95% CIs.</p><table-wrap position="float" id="jah310366-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Patient Characteristics by Stroke Pathogenesis</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">Overall, n=3995<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Undetermined pathogenesis, n=863<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Cervical artery dissection, n=631<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">PFO, n=607<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Cardiac embolism, n=547<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Other determined pathogenesis, n=382<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Small&#x02010;vessel disease, n=370<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">Large&#x02010;artery atherosclerosis, n=370<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">&#x0003e;1 possible pathogenesis, n=225<xref rid="jah310366-note-0007" ref-type="table-fn">*</xref>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> value<xref rid="jah310366-note-0008" ref-type="table-fn">&#x02020;</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">48.2 (41.5&#x02013;52.1)</td><td align="left" rowspan="1" colspan="1">48.6 (42.9&#x02013;52.4)</td><td align="left" rowspan="1" colspan="1">44.7 (38.2&#x02013;50.4)</td><td align="left" rowspan="1" colspan="1">44.9 (36.5&#x02013;50.4)</td><td align="left" rowspan="1" colspan="1">49.5 (43.9&#x02013;52.7)</td><td align="left" rowspan="1" colspan="1">47.2 (38.9&#x02013;51.4)</td><td align="left" rowspan="1" colspan="1">50.3 (46.5&#x02013;52.9)</td><td align="left" rowspan="1" colspan="1">51.3 (47.5&#x02013;53.6)</td><td align="left" rowspan="1" colspan="1">49.7 (43.8&#x02013;52.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex</td><td align="left" rowspan="1" colspan="1">3992</td><td align="left" rowspan="1" colspan="1">2627 (66)</td><td align="left" rowspan="1" colspan="1">547 (63)</td><td align="left" rowspan="1" colspan="1">422 (67)</td><td align="left" rowspan="1" colspan="1">372 (61)</td><td align="left" rowspan="1" colspan="1">375 (69)</td><td align="left" rowspan="1" colspan="1">212 (55)</td><td align="left" rowspan="1" colspan="1">278 (75)</td><td align="left" rowspan="1" colspan="1">273 (74)</td><td align="left" rowspan="1" colspan="1">148 (66)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="left" rowspan="1" colspan="1">3202</td><td align="left" rowspan="1" colspan="1">25.7 (23.1&#x02013;29.3)</td><td align="left" rowspan="1" colspan="1">26.2 (23.5, 29.7)</td><td align="left" rowspan="1" colspan="1">24.7 (22.5&#x02013;27.7)</td><td align="left" rowspan="1" colspan="1">24.7 (22.1&#x02013;28.0)</td><td align="left" rowspan="1" colspan="1">26.3 (23.7, 30.6)</td><td align="left" rowspan="1" colspan="1">25.4 (22.3&#x02013;28.2)</td><td align="left" rowspan="1" colspan="1">26.8 (24.2&#x02013;31.3)</td><td align="left" rowspan="1" colspan="1">26.5 (24.2&#x02013;30.1)</td><td align="left" rowspan="1" colspan="1">25.8 (23.1&#x02013;28.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">1485 (37)</td><td align="left" rowspan="1" colspan="1">316 (37)</td><td align="left" rowspan="1" colspan="1">169 (27)</td><td align="left" rowspan="1" colspan="1">73 (12)</td><td align="left" rowspan="1" colspan="1">229 (42)</td><td align="left" rowspan="1" colspan="1">114 (30)</td><td align="left" rowspan="1" colspan="1">275 (74)</td><td align="left" rowspan="1" colspan="1">222 (60)</td><td align="left" rowspan="1" colspan="1">87 (39)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">3988</td><td align="left" rowspan="1" colspan="1">2206 (55)</td><td align="left" rowspan="1" colspan="1">512 (59)</td><td align="left" rowspan="1" colspan="1">263 (42)</td><td align="left" rowspan="1" colspan="1">273 (45)</td><td align="left" rowspan="1" colspan="1">296 (54)</td><td align="left" rowspan="1" colspan="1">158 (41)</td><td align="left" rowspan="1" colspan="1">294 (79)</td><td align="left" rowspan="1" colspan="1">273 (74)</td><td align="left" rowspan="1" colspan="1">137 (61)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">416 (10)</td><td align="left" rowspan="1" colspan="1">75 (8.7)</td><td align="left" rowspan="1" colspan="1">26 (4.1)</td><td align="left" rowspan="1" colspan="1">13 (2.1)</td><td align="left" rowspan="1" colspan="1">65 (12)</td><td align="left" rowspan="1" colspan="1">25 (6.5)</td><td align="left" rowspan="1" colspan="1">88 (24)</td><td align="left" rowspan="1" colspan="1">94 (25)</td><td align="left" rowspan="1" colspan="1">30 (13)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">3987</td><td align="left" rowspan="1" colspan="1">1522 (38)</td><td align="left" rowspan="1" colspan="1">370 (43)</td><td align="left" rowspan="1" colspan="1">145 (23)</td><td align="left" rowspan="1" colspan="1">177 (29)</td><td align="left" rowspan="1" colspan="1">204 (37)</td><td align="left" rowspan="1" colspan="1">140 (37)</td><td align="left" rowspan="1" colspan="1">187 (51)</td><td align="left" rowspan="1" colspan="1">204 (55)</td><td align="left" rowspan="1" colspan="1">95 (42)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of vascular risk factors</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">1.0 (1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">1.0 (0.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">1.0 (0.0, 2.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">1.0 (0.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">2.0 (2.0, 3.0)</td><td align="left" rowspan="1" colspan="1">2.0 (2.0&#x02013;3.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;2.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">182 (4.6)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">3 (0.5)</td><td align="left" rowspan="1" colspan="1">3 (0.5)</td><td align="left" rowspan="1" colspan="1">155 (28)</td><td align="left" rowspan="1" colspan="1">7 (1.8)</td><td align="left" rowspan="1" colspan="1">4 (1.1)</td><td align="left" rowspan="1" colspan="1">3 (0.8)</td><td align="left" rowspan="1" colspan="1">7 (3.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary heart disease</td><td align="left" rowspan="1" colspan="1">3988</td><td align="left" rowspan="1" colspan="1">188 (4.7)</td><td align="left" rowspan="1" colspan="1">30 (3.5)</td><td align="left" rowspan="1" colspan="1">6 (1.0)</td><td align="left" rowspan="1" colspan="1">3 (0.5)</td><td align="left" rowspan="1" colspan="1">84 (15)</td><td align="left" rowspan="1" colspan="1">16 (4.2)</td><td align="left" rowspan="1" colspan="1">13 (3.5)</td><td align="left" rowspan="1" colspan="1">21 (5.7)</td><td align="left" rowspan="1" colspan="1">15 (6.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Prosthetic valves</td><td align="left" rowspan="1" colspan="1">3990</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3901 (98)</td><td align="left" rowspan="1" colspan="1">861 (100)</td><td align="left" rowspan="1" colspan="1">629 (100)</td><td align="left" rowspan="1" colspan="1">606 (100)</td><td align="left" rowspan="1" colspan="1">479 (88)</td><td align="left" rowspan="1" colspan="1">372 (98)</td><td align="left" rowspan="1" colspan="1">369 (100)</td><td align="left" rowspan="1" colspan="1">368 (100)</td><td align="left" rowspan="1" colspan="1">217 (96)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mechanical</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">68 (1.7)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (0.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">58 (11)</td><td align="left" rowspan="1" colspan="1">4 (1.0)</td><td align="left" rowspan="1" colspan="1">1 (0.3)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">4 (1.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Biological</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21 (0.5)</td><td align="left" rowspan="1" colspan="1">1 (0.1)</td><td align="left" rowspan="1" colspan="1">1 (0.2)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">10 (1.8)</td><td align="left" rowspan="1" colspan="1">5 (1.3)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">4 (1.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (&#x0003c;35%)</td><td align="left" rowspan="1" colspan="1">3118</td><td align="left" rowspan="1" colspan="1">72 (2.3)</td><td align="left" rowspan="1" colspan="1">3 (0.4)</td><td align="left" rowspan="1" colspan="1">3 (0.6)</td><td align="left" rowspan="1" colspan="1">2 (0.4)</td><td align="left" rowspan="1" colspan="1">57 (14)</td><td align="left" rowspan="1" colspan="1">3 (1.0)</td><td align="left" rowspan="1" colspan="1">1 (0.4)</td><td align="left" rowspan="1" colspan="1">1 (0.4)</td><td align="left" rowspan="1" colspan="1">2 (1.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior transient ischemic attack</td><td align="left" rowspan="1" colspan="1">3995</td><td align="left" rowspan="1" colspan="1">110 (2.8)</td><td align="left" rowspan="1" colspan="1">20 (2.3)</td><td align="left" rowspan="1" colspan="1">16 (2.5)</td><td align="left" rowspan="1" colspan="1">9 (1.5)</td><td align="left" rowspan="1" colspan="1">13 (2.4)</td><td align="left" rowspan="1" colspan="1">13 (3.4)</td><td align="left" rowspan="1" colspan="1">11 (3.0)</td><td align="left" rowspan="1" colspan="1">23 (6.2)</td><td align="left" rowspan="1" colspan="1">5 (2.2)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior intracerebral hemorrhage</td><td align="left" rowspan="1" colspan="1">3994</td><td align="left" rowspan="1" colspan="1">31 (0.8)</td><td align="left" rowspan="1" colspan="1">11 (1.3)</td><td align="left" rowspan="1" colspan="1">1 (0.2)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td><td align="left" rowspan="1" colspan="1">5 (0.9)</td><td align="left" rowspan="1" colspan="1">7 (1.8)</td><td align="left" rowspan="1" colspan="1">1 (0.3)</td><td align="left" rowspan="1" colspan="1">3 (0.8)</td><td align="left" rowspan="1" colspan="1">3 (1.3)</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol, mmol/L</td><td align="left" rowspan="1" colspan="1">3187</td><td align="left" rowspan="1" colspan="1">4.9 (4.1 5.7)</td><td align="left" rowspan="1" colspan="1">5.0 (4.2&#x02013;5.7)</td><td align="left" rowspan="1" colspan="1">4.7 (3.9&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1">4.5 (3.9&#x02013;5.2)</td><td align="left" rowspan="1" colspan="1">4.7 (3.9&#x02013;5.7)</td><td align="left" rowspan="1" colspan="1">4.5 (3.8&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1">5.3 (4.6&#x02013;6.0)</td><td align="left" rowspan="1" colspan="1">5.4 (4.5&#x02013;6.3)</td><td align="left" rowspan="1" colspan="1">4.9 (4.0&#x02013;5.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Low&#x02010;density lipoprotein cholesterol, mmol/L</td><td align="left" rowspan="1" colspan="1">3144</td><td align="left" rowspan="1" colspan="1">3.0 (2.3&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">3.1 (2.4&#x02013;3.7)</td><td align="left" rowspan="1" colspan="1">2.8 (2.2&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">2.7 (2.1&#x02013;3.3)</td><td align="left" rowspan="1" colspan="1">2.9 (2.2&#x02013;3.8)</td><td align="left" rowspan="1" colspan="1">2.7 (2.1&#x02013;3.4)</td><td align="left" rowspan="1" colspan="1">3.4 (2.8&#x02013;4.1)</td><td align="left" rowspan="1" colspan="1">3.5 (2.6&#x02013;4.3)</td><td align="left" rowspan="1" colspan="1">3.1 (2.3&#x02013;3.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Initial National Institutes of Health Stroke Scale score</td><td align="left" rowspan="1" colspan="1">3951</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;7.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;6.0)</td><td align="left" rowspan="1" colspan="1">2.0 (0.0&#x02013;8.0)</td><td align="left" rowspan="1" colspan="1">2.0 (0.0, 4.0)</td><td align="left" rowspan="1" colspan="1">4.0 (1.0&#x02013;9.0)</td><td align="left" rowspan="1" colspan="1">3.0 (1.0&#x02013;9.0)</td><td align="left" rowspan="1" colspan="1">2.0 (1.0&#x02013;4.0)</td><td align="left" rowspan="1" colspan="1">3.0 (1.0&#x02013;10.0)</td><td align="left" rowspan="1" colspan="1">3.0 (1.0&#x02013;6.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Transthoracic echocardiogram</td><td align="left" rowspan="1" colspan="1">3559</td><td align="left" rowspan="1" colspan="1">2384 (67)</td><td align="left" rowspan="1" colspan="1">551 (72)</td><td align="left" rowspan="1" colspan="1">289 (52)</td><td align="left" rowspan="1" colspan="1">366 (68)</td><td align="left" rowspan="1" colspan="1">358 (71)</td><td align="left" rowspan="1" colspan="1">215 (63)</td><td align="left" rowspan="1" colspan="1">255 (76)</td><td align="left" rowspan="1" colspan="1">205 (64)</td><td align="left" rowspan="1" colspan="1">145 (71)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Transesophageal echocardiogram</td><td align="left" rowspan="1" colspan="1">3521</td><td align="left" rowspan="1" colspan="1">1355 (38)</td><td align="left" rowspan="1" colspan="1">369 (48)</td><td align="left" rowspan="1" colspan="1">48 (8.7)</td><td align="left" rowspan="1" colspan="1">382 (72)</td><td align="left" rowspan="1" colspan="1">175 (35)</td><td align="left" rowspan="1" colspan="1">141 (41)</td><td align="left" rowspan="1" colspan="1">85 (26)</td><td align="left" rowspan="1" colspan="1">70 (22)</td><td align="left" rowspan="1" colspan="1">85 (43)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Start antiplatelet therapy</td><td align="left" rowspan="1" colspan="1">3991</td><td align="left" rowspan="1" colspan="1">2205 (55)</td><td align="left" rowspan="1" colspan="1">514 (60)</td><td align="left" rowspan="1" colspan="1">348 (55)</td><td align="left" rowspan="1" colspan="1">316 (52)</td><td align="left" rowspan="1" colspan="1">201 (37)</td><td align="left" rowspan="1" colspan="1">177 (46)</td><td align="left" rowspan="1" colspan="1">288 (78)</td><td align="left" rowspan="1" colspan="1">225 (61)</td><td align="left" rowspan="1" colspan="1">136 (60)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Start anticoagulants</td><td align="left" rowspan="1" colspan="1">3990</td><td align="left" rowspan="1" colspan="1">300 (7.5)</td><td align="left" rowspan="1" colspan="1">25 (2.9)</td><td align="left" rowspan="1" colspan="1">83 (13)</td><td align="left" rowspan="1" colspan="1">21 (3.5)</td><td align="left" rowspan="1" colspan="1">89 (16)</td><td align="left" rowspan="1" colspan="1">32 (8.4)</td><td align="left" rowspan="1" colspan="1">8 (2.2)</td><td align="left" rowspan="1" colspan="1">22 (5.9)</td><td align="left" rowspan="1" colspan="1">20 (8.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Intravenous thrombolysis</td><td align="left" rowspan="1" colspan="1">3847</td><td align="left" rowspan="1" colspan="1">1073 (28)</td><td align="left" rowspan="1" colspan="1">256 (31)</td><td align="left" rowspan="1" colspan="1">161 (27)</td><td align="left" rowspan="1" colspan="1">215 (36)</td><td align="left" rowspan="1" colspan="1">165 (31)</td><td align="left" rowspan="1" colspan="1">74 (20)</td><td align="left" rowspan="1" colspan="1">60 (17)</td><td align="left" rowspan="1" colspan="1">99 (28)</td><td align="left" rowspan="1" colspan="1">43 (20)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Intra&#x02010;arterial treatment</td><td align="left" rowspan="1" colspan="1">3849</td><td align="left" rowspan="1" colspan="1">769 (20)</td><td align="left" rowspan="1" colspan="1">152 (18)</td><td align="left" rowspan="1" colspan="1">156 (26)</td><td align="left" rowspan="1" colspan="1">95 (16)</td><td align="left" rowspan="1" colspan="1">143 (27)</td><td align="left" rowspan="1" colspan="1">85 (23)</td><td align="left" rowspan="1" colspan="1">3 (0.8)</td><td align="left" rowspan="1" colspan="1">95 (27)</td><td align="left" rowspan="1" colspan="1">40 (19)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">mRS score at follow&#x02010;up, 0&#x02013;2 (vs 3&#x02013;6)</td><td align="left" rowspan="1" colspan="1">3445</td><td align="left" rowspan="1" colspan="1">3009 (87)</td><td align="left" rowspan="1" colspan="1">671 (90)</td><td align="left" rowspan="1" colspan="1">463 (84)</td><td align="left" rowspan="1" colspan="1">513 (96)</td><td align="left" rowspan="1" colspan="1">398 (85)</td><td align="left" rowspan="1" colspan="1">261 (76)</td><td align="left" rowspan="1" colspan="1">282 (93)</td><td align="left" rowspan="1" colspan="1">253 (82)</td><td align="left" rowspan="1" colspan="1">168 (85)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Recurrent stroke until follow&#x02010;up</td><td align="left" rowspan="1" colspan="1">3394</td><td align="left" rowspan="1" colspan="1">76 (2.2)</td><td align="left" rowspan="1" colspan="1">21 (2.8)</td><td align="left" rowspan="1" colspan="1">13 (2.4)</td><td align="left" rowspan="1" colspan="1">2 (0.4)</td><td align="left" rowspan="1" colspan="1">9 (2.0)</td><td align="left" rowspan="1" colspan="1">11 (3.4)</td><td align="left" rowspan="1" colspan="1">6 (2.0)</td><td align="left" rowspan="1" colspan="1">9 (3.0)</td><td align="left" rowspan="1" colspan="1">5 (2.6)</td><td align="left" rowspan="1" colspan="1">0.076</td></tr></tbody></table><table-wrap-foot id="jah310366-ntgp-0002"><fn id="jah310366-note-0006"><p>mRS indicates modified Rankin Scale; and PFO, patent foramen ovale.</p></fn><fn id="jah310366-note-0007"><label>*</label><p>Median (interquartile range) or frequency (%).</p></fn><fn id="jah310366-note-0008"><label>
<sup>&#x02020;</sup>
</label><p>Kruskal&#x02013;Wallis rank&#x02010;sum test; Pearson's &#x003c7;<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><p>All analyses were performed with RStudio version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria). Data S3 provides package details. Our reporting adheres to the Strengthening the Reporting of Observational studies in Epidemiology guidelines.<xref rid="jah310366-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p></sec></sec><sec sec-type="results" id="jah310366-sec-0017"><title>Results</title><p>Among 8158 individuals aged 18 to 55&#x02009;years with AIS, transient ischemic attack, or mimics, 4556 (60%) were identified with first&#x02010;ever AIS confirmed by imaging (Figure&#x000a0;<xref rid="jah310366-fig-0001" ref-type="fig">1</xref>). After exclusions for incomplete diagnostics (n=560), 3996 patients (median age, 48.2 [IQR, 41.5&#x02013;52.1] years; 66% male sex) were analyzed: 863 with undetermined pathogenesis and 3132 with determined pathogenesis (Figure&#x000a0;<xref rid="jah310366-fig-0002" ref-type="fig">2</xref>). Three&#x02010;month follow&#x02010;up was available for 3445 patients (86.2%). Of 943 patients aged 18 to 45&#x02009;years, 773 had determined pathogenesis and 170 undetermined. Follow&#x02010;up data were available for 818 (662 determined, 156 undetermined). Of 3052 patients aged 46 to 55&#x02009;years, 2359 (77.3%) had determined pathogenesis and 693 undetermined. Follow&#x02010;up data were available for 2627 (2035 determined, 592 undetermined).</p><fig position="float" fig-type="Figure" id="jah310366-fig-0001"><label>Figure 1</label><caption><title>Patient flowchart.</title><p>AF indicates atrial fibrillation; BPV, biological prosthetic valve; ESUS, embolic stroke of unknown source; LEF, low ejection fraction; MPV, mechanical prosthetic valve; mRS, modified Rankin Scale; PFO, patent foramen ovale; SVD, small&#x02010;vessel disease; and TIA, transient ischemic attack.</p></caption><graphic xlink:href="JAH3-13-e036761-g002" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="Figure" id="jah310366-fig-0002"><label>Figure 2</label><caption><title>Distribution of stroke pathogenesis.</title><p>(<bold>A</bold>), All patients; (<bold>B</bold>), patients aged 18&#x02013;45 y, (<bold>C</bold>), patients aged 46&#x02013;55 y. PFO indicates patent foramen ovale.</p></caption><graphic xlink:href="JAH3-13-e036761-g004" position="anchor" id="jats-graphic-3"/></fig><p>AIS with undetermined pathogenesis after complete diagnostic evaluation (863 cases [22%]) was more prevalent than any single determined pathogenesis (<xref rid="jah310366-tbl-0001" ref-type="table">Table</xref> 1). Sex distribution was similar between patients with undetermined and determined stroke pathogenesis, with a higher proportion of men in the small&#x02010;vessel disease (75%) and large&#x02010;artery atherosclerosis groups (74%; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S1</xref>). Determined pathogenesis cases included PFO (15%), cervical artery dissection (16%), and cardiac embolism (excluding PFO or other rare cardiac causes; 14%). Other determined pathogeneses comprised small&#x02010;vessel disease and large&#x02010;artery atherosclerosis (&#x02265;50% stenosis; each 9.3%), and multiple potential pathogeneses in 5.6% of cases. A total of 9.6% of patients had a stroke of other determined pathogenesis, with notable shifts in the distribution of determined pathogeneses between age groups 18 to 45 and 46&#x02013;55&#x02009;years (see Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><sec id="jah310366-sec-0018"><title>Vascular Risk Factors</title><p>The most common risk factors were dyslipidemia (55%), smoking (38%), and arterial hypertension (37%). Analyses revealed differences in vascular risk profiles between patients with undetermined and determined pathogenesis. Those with undetermined pathogenesis had slightly higher body mass index compared with those with determined pathogeneses (median, 26.2 versus 25.7 kg/m<sup>2</sup>, <italic toggle="yes">P</italic>=0.004) and higher rates of dyslipidemia (59% versus 54%, <italic toggle="yes">P</italic>=0.007) and smoking (43% versus 37%, <italic toggle="yes">P</italic>=0.001). The proportion of patients with at least 1 vascular risk factor was higher in the undetermined group (83% versus 77%, <italic toggle="yes">P</italic>&#x0003c;0.001; Figure&#x000a0;<xref rid="jah310366-fig-0003" ref-type="fig">3B</xref>). The risk profile of undetermined pathogenesis patients resembled those with cardiac embolism and multiple possible pathogeneses, with similar rates of smoking, arterial hypertension, diabetes, and dyslipidemia (Table&#x000a0;<xref rid="jah310366-tbl-0001" ref-type="table">1</xref> and Figure&#x000a0;<xref rid="jah310366-fig-0003" ref-type="fig">3A</xref>). Patients with cardiac embolism had the highest incidence of atrial fibrillation (28%), coronary heart disease (15%), prosthetic valves (mechanical, 11%; biological, 1.8%), and low cardiac output (15%). Both follow&#x02010;up transthoracic echocardiogram (72% versus 66%, <italic toggle="yes">P</italic>=0.001) and transesophageal echocardiogram (48% versus 36%, <italic toggle="yes">P</italic>&#x0003c;0.001) were performed more frequently in patients with undetermined pathogenesis than in patients with determined pathogenesis.</p><fig position="float" fig-type="Figure" id="jah310366-fig-0003"><label>Figure 3</label><caption><title>Vascular risk factors with hold&#x02010;adjusted Wilcoxon group comparisons of the number of vascular risk factors between patients with undetermined and specific determined pathogeneses (A, B) and distribution of mRS scores at 3&#x02009;months (C) by stroke pathogenesis.</title><p>mRS indicates modified Rankin Scale; and PFO, patent foramen ovale.</p></caption><graphic xlink:href="JAH3-13-e036761-g003" position="anchor" id="jats-graphic-5"/></fig><p>In the age subgroup analyses, the number of vascular risk factors was higher in the undetermined compared with the determined pathogenesis group for patients aged 18 to 45 (median, 1 [IQR, 0&#x02013;2] years versus median, 1 [IQR, 0&#x02013;2]; <italic toggle="yes">P</italic>=0.011). No significant differences were found in the age group 46&#x02013;55&#x02009;years (see Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref> and Figure&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="jah310366-sec-0019"><title>Stroke Severity and Acute Treatment</title><p>Initial National Institutes of Health Stroke Scale scores were generally low (median, 2 [IQR, 1&#x02013;7]; <xref rid="jah310366-tbl-0001" ref-type="table">Table</xref> 1), highest among cardiac embolism (median, 4 [IQR, 1&#x02013;9]), large&#x02010;artery atherosclerosis (median, 3 [IQR, 1&#x02013;10]), other determined pathogenesis (median, 3 [IQR, 1&#x02013;9]), and multiple possible pathogenesis groups (median, 3 [IQR, 1&#x02013;6]), without evident differences between undetermined and determined pathogeneses (median, 2 [IQR, 1&#x02013;6] versus median, 2 [IQR, 1&#x02013;7]; <italic toggle="yes">P</italic>&#x0003e;0.9).</p><p>IVT was administered in 28% of cases, more frequently in patients with undetermined pathogenesis compared to those with determined pathogeneses (31% versus 27%, <italic toggle="yes">P</italic>=0.046), with the highest usage in patients with PFO (36%) and the lowest in small&#x02010;vessel disease and other determined pathogenesis groups (17% and 20%, respectively). IAT was performed in 20% of cases, with the highest rates observed in patients with large&#x02010;artery atherosclerosis, cardiac embolism (each 27%), and cervical artery dissection (26%) as compared with a rate of 18% in the undetermined pathogenesis group. In the age subgroup analyses, no significant differences in IVT and IAT rates were observed between patients with undetermined and determined pathogenesis.</p></sec><sec id="jah310366-sec-0020"><title>Functional Outcomes</title><p>Excellent functional outcome (mRS score, 0&#x02013;1) at 3 months was achieved by 67%, and favorable (mRS score, 0&#x02013;2) by 87% (Table&#x000a0;<xref rid="jah310366-tbl-0001" ref-type="table">1</xref>). Strokes of undetermined pathogenesis had higher rates of favorable outcomes compared with those with determined origin (90% versus 87%, <italic toggle="yes">P</italic>=0.033; Figure&#x000a0;<xref rid="jah310366-fig-0003" ref-type="fig">3C</xref> and Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S1</xref>). This difference was particularly evident in the 46 to 55&#x02009;years age group, where the undetermined pathogenesis group had higher rates of both excellent and favorable outcomes compared with the determined pathogenesis group (mRS score, 0&#x02013;1: 70% versus 64%, <italic toggle="yes">P</italic>=0.013; mRS score, 0&#x02013;2: 89% versus 85%, <italic toggle="yes">P</italic>=0.023; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref>). In contrast, there were no significant differences in outcomes between the groups in the 18 to 45&#x02009;years age group (mRS score, 0&#x02013;1: 71% versus 72%, <italic toggle="yes">P</italic>=0.8; mRS score, 0&#x02013;2: 93% versus 92%, <italic toggle="yes">P</italic>=0.7). The highest proportions of unfavorable outcomes (mRS score, 3&#x02013;6) were seen in patients with other determined pathogenesis (24%).</p><p>Logistic regression analyses revealed that the odds of favorable outcomes (mRS score, 0&#x02013;2; see Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S3</xref>) decreased with age (adjusted odds ratio [aOR], 0.95 [95% CI, 0.93&#x02013;0.96]), while there was a positive interaction effect between age and undetermined pathogenesis (aOR, 1.04 [95% CI, 1.00&#x02013;1.08]). The main effect of undetermined pathogenesis, male sex, and the interaction between age and sex were not significant predictors of favorable outcomes. In the sensitivity analysis for the 18 to 45&#x02009;years age subgroup (Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S4</xref>), only age remained a significant predictor of lower odds of favorable outcomes (aOR, 0.95 [95% CI, 0.89&#x02013;1.00]), with other factors not reaching statistical significance. In the 46 to 55&#x02009;years age subgroup (Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S5</xref>), the odds of favorable outcomes decreased with age (aOR, 0.92 [95% CI, 0.89&#x02013;0.95]), while a stronger positive interaction effect between age and undetermined pathogenesis was observed (aOR, 1.15 [95% CI, 1.07&#x02013;1.28]; for excellent functional outcomes see Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S6&#x02013;S8</xref>). The main effects of undetermined pathogenesis, male sex, and the age&#x02013;sex interaction remained nonsignificant in this subgroup.</p><p>The logistic regression model including the modified TOAST classification revealed that PFO (aOR, 2.35 [95% CI, 1.46&#x02013;3.92]; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S9</xref> and Figure&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref>) and small&#x02010;vessel disease (aOR, 1.78 [95% CI, 1.08&#x02013;3.04]) had higher odds for favorable outcomes (mRS score, 0&#x02013;2) compared with undetermined pathogeneses, whereas other determined stroke pathogeneses (aOR, 0.34 [95% CI, 0.24&#x02013;0.49]), cervical artery dissection (aOR, 0.55 [95% CI, 0.39&#x02013;0.77]), large&#x02010;artery atherosclerosis (aOR, 0.61 [95% CI, 0.42&#x02013;0.90]), and cardiac embolism (aOR, 0.71 [95% CI, 0.50&#x02013;1.01]) were associated with lower odds (for excellent outcomes [mRS score, 0&#x02013;1] see Figure&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><p>For excellent outcomes (mRS score, 0&#x02013;1; Tables&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S6</xref> and <xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S10</xref>, and Figure&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S2</xref>), age was associated with lower odds (aOR, 0.97 [95% CI, 0.96&#x02013;0.98]). There was a positive interaction effect between age and undetermined pathogenesis (aOR, 1.03 [95% CI, 1.00&#x02013;1.05), but no significant main effect of undetermined stroke pathogenesis. In the sensitivity analysis for the age 18 to 45&#x02009;years subgroup (Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S7</xref>), both the negative main effect of age (aOR, 0.94 [95% CI, 0.91&#x02013;0.97]) and the positive interaction effect between age and undetermined pathogenesis (aOR, 1.08 [95% CI, 1.01&#x02013;1.16]) remained significant. In contrast, no significant effects were observed in the age 46 to 55&#x02009;years subgroup (Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S8</xref>). PFO&#x02010;related strokes were associated with higher odds (aOR, 1.36 [95% CI, 1.05&#x02013;1.76]; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S10</xref>), while other stroke pathogeneses (aOR, 0.53 [95% CI, 0.41&#x02013;0.69]), cervical artery dissection (aOR, 0.55 [95% CI, 0.43&#x02013;0.69), and large&#x02010;artery atherosclerosis (aOR, 0.71 [95% CI, 0.53&#x02013;0.94]) had lower odds.</p></sec><sec id="jah310366-sec-0021"><title>Ischemic Stroke Recurrence Within 3 Months</title><p>In the Fine&#x02013;Gray proportional hazards models, patients with undetermined pathogenesis exhibited a higher risk of stroke recurrence within 3 months compared with those with determined pathogenesis (adjusted hazard ratio [aHR], 1.72 [95% CI, 1.01&#x02013;2.94]; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S11</xref>). Subgroup analyses by age revealed that this increased risk was particularly pronounced in the age 18 to 45&#x02009;years group with undetermined pathogenesis (aHR, 3.42 [95% CI, 1.15&#x02013;9.11]; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S12</xref>). In contrast, there was no significant difference in stroke recurrence risk between undetermined and determined pathogeneses in the age 46&#x02013;55&#x02009;years group (aHR, 1.37 [95% CI, 0.73&#x02013;2.57]; Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S13</xref>). Comparing undetermined pathogenesis with each specific stroke pathogenesis (Table&#x000a0;<xref rid="jah310366-supitem-0001" ref-type="supplementary-material">S14</xref>), PFO presented a lower recurrence risk compared with undetermined pathogenesis (aHR, 0.12 [95% CI, 0.03&#x02013;0.54]), while other pathogeneses showed no difference. Cumulative incidence graphs illustrate stroke recurrence and death by pathogenetic groups (Figure&#x000a0;<xref rid="jah310366-fig-0004" ref-type="fig">4</xref>).</p><fig position="float" fig-type="Figure" id="jah310366-fig-0004"><label>Figure 4</label><caption><title>Cumulative incidence of stroke recurrence and death by stroke pathogenesis.</title><p>
<bold>A</bold>, All patients, dichotomized pathogeneses (undetermined vs determined); (<bold>B</bold>) all patients, modified <styled-content style="fixed-case" toggle="no">TOAST</styled-content> pathogeneses; (<bold>C</bold>)&#x000a0;patients aged 18&#x02013;45 y, dichotomized pathogeneses; (<bold>D</bold>) patients aged 46&#x02013;55 y, dichotomized pathogeneses.</p><p>mRS indicates modified Rankin Scale; PFO, patent foramen ovale; and TOAST, Trial of ORG 10172 in Acute Stroke Treatment.</p></caption><graphic xlink:href="JAH3-13-e036761-g001" position="anchor" id="jats-graphic-7"/></fig></sec></sec><sec sec-type="discussion" id="jah310366-sec-0022"><title>Discussion</title><p>This study investigated the stroke pathogeneses in young adults aged 18 to 55&#x02009;years across Switzerland, focusing on contrasting undetermined and determined causes. Our main findings are (1) traditional vascular risk factors are highly prevalent in both patients with undetermined and determined AIS pathogenesis; (2) rates of IVT and IAT were overall high in the studied population, with patients with undetermined pathogenesis being more likely to receive IVT; (3) patients with undetermined pathogenesis aged 46 to 55&#x02009;years exhibited more favorable 3&#x02010;month functional outcomes compared with those with determined pathogenesis, while no significant differences were found in the age 18 to 45&#x02009;years group; (4) AIS recurrence rates within 3 months were higher in patients with undetermined pathogenesis compared with those with determined pathogenesis, particularly in the age 18 to 45&#x02009;years group; and (5) there were pronounced age disparities in patients with undetermined pathogenesis, with higher stroke recurrence rates in the age 18 to 45&#x02009;years group and better functional outcomes in the age 46 to 55&#x02009;years group compared with those with determined pathogenesis.</p><p>We found that &#x02248;22% of AIS in young adults (aged 18&#x02013;55&#x02009;years) had undetermined pathogenesis, with a lower rate of 18% in patients aged 18 to 45&#x02009;years. This corresponds closely to the 25.2% observed in a recent Dutch multicenter study.<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Vascular risk factors were prevalent among patients with AIS with dyslipidemia (55%), current smoking (38%), and arterial hypertension (37%) being the most common, showing a rise in dyslipidemia compared with the rates reported by Putaala et&#x000a0;al,<xref rid="jah310366-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> where dyslipidemia was 45.8%, current smoking 48.7%, and hypertension 35.9%. Patients with undetermined stroke pathogenesis exhibited higher body mass index and increased rates of dyslipidemia and smoking but remarkably a trend toward less diabetes than those with determined pathogeneses. While these vascular risk factors were less common in patients with undetermined pathogenesis compared with those with small&#x02010;vessel or large&#x02010;artery atherosclerosis strokes, which are known to be highly associated with these risk factors,<xref rid="jah310366-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jah310366-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> the similarity in risk profiles between undetermined pathogenesis and cardiac embolism may suggest potential hidden cardioembolic mechanisms underlying cryptogenic embolic stroke.<xref rid="jah310366-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jah310366-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Overall, the number of vascular risk factors was higher in patients with undetermined pathogenesis compared with those with determined pathogenesis, particularly in the age 18&#x02013;45&#x02009;years group. The findings reinforce the results of a recent Dutch multicenter study involving 1322 patients with AIS aged 18 to 49&#x02009;years, showing that traditional vascular risk factors were frequent in cryptogenic AIS.<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Regarding revascularization therapies, we observed high rates of IVT (28% versus 18.2%<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>) and IAT (20% versus 2.6%<xref rid="jah310366-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>), exceeding IVT rates in the UK and US general stroke population (11%&#x02013;12%<xref rid="jah310366-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jah310366-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>) and the European Stroke Action Plan's 15% target for 2018 to 2030.<xref rid="jah310366-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Notably, patients with undetermined pathogenesis had slightly higher IVT rates (31%) than the determined pathogenesis group (27%), particularly compared with patients with small&#x02010;vessel disease (17%). IAT rates were similar between undetermined (18%) and determined pathogeneses (20%), but higher in specific pathogeneses like cardiac embolism (27%), large&#x02010;artery atherosclerosis (27%), and cervical artery dissection (26%). The preference for antiplatelets over anticoagulation in cases with undetermined pathogenesis aligns with the NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) and RE&#x02010;SPECT ESUS (Randomized, Double&#x02010;Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate Versus Acetylsalicylic Acid in Patients With Embolic Stroke of Undetermined Source) trial findings, which showed no benefit of oral anticoagulation over aspirin in cryptogenic embolic stroke.<xref rid="jah310366-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jah310366-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>Our third finding was that two thirds of young patients with AIS achieved excellent functional outcome (mRS score, 0&#x02013;1) at 3 months, and 87% attained good functional outcomes (mRS score, 0&#x02013;2), corresponding to the results from the SYSS (Swiss Young Stroke Study; young patients aged 16&#x02013;55&#x02009;years with AIS; 61% for mRS score, 0&#x02013;1)<xref rid="jah310366-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> and an older Swiss analysis (68% for mRS score, 0&#x02013;1)<xref rid="jah310366-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> without showing increased favorable outcomes with improved access to intra&#x02010;arterial interventions. The undetermined pathogenesis group did not achieve the highest favorable outcome rates seen in PFO (77%) and small&#x02010;vessel disease (75%), nor the lowest observed in other determined causes (56%) and cervical artery dissection (58%). Patients with undetermined pathogenesis had a 90% chance of good outcome, slightly higher than the 87% in the determined pathogenesis group. Outcome disparities across pathogeneses were evident, with PFO and small&#x02010;vessel disease being more likely, and those with other determined pathogeneses being less likely to achieve favorable functional outcomes. Outcome disparities were more pronounced in the age 46 to 55&#x02009;years group (mRS score, 0&#x02013;1: 70% versus 64%; mRS score, 0&#x02013;2: 89% versus 85%), with no significant differences in the age 18&#x02013;45&#x02009;years group (mRS score, 0&#x02013;1: 71% versus 72%; mRS score, 0&#x02013;2: 93% versus 92%, <italic toggle="yes">P</italic>=0.7).</p><p>Significant interaction effects suggest that the odds of excellent and favorable outcomes decrease less with age in the undetermined pathogenesis group compared with the determined group, especially for excellent outcomes in ages 18 to 45&#x02009;years and favorable outcomes in ages 46 to 55&#x02009;years. This age disparity cannot be solely explained by differing proportions of determined stroke pathogeneses. While the proportion of large&#x02010;artery atherosclerosis and cardioembolic strokes (associated with worse outcomes) increased with age, the proportion of cervical artery dissection (also associated with worse outcomes) decreased, and small&#x02010;vessel disease strokes (associated with better outcomes) increased in the age 46 to 55&#x02009;years group. Further investigation is needed to understand the reasons behind this age disparity.</p><p>AIS recurrence within 3 months was higher in the undetermined pathogenesis group (2.8%) than in the determined pathogenesis group (2.1%), a statistically significant difference when accounting for the competing risk of death. Pronounced age disparities were observed, with significantly higher AIS recurrence rates in the undetermined pathogenesis group (4.5%) versus the determined pathogenesis group (1.8%) among patients aged 18 to 45&#x02009;years, as indicated by Fine&#x02013;Gray proportional hazards models. No significant differences were found in the age 46 to 55&#x02009;years group (2.4% versus 2.2%).</p><p>While a lower recurrence rate of stroke in patients with PFO partially explains the difference between undetermined and determined pathogenesis groups, further research is needed to explore the high rate of recurrent AIS within 3 months in patients aged 18 to 45&#x02009;years with undetermined stroke pathogenesis.</p><p>The overall 2.8% 3&#x02010;month recurrence rate in patients with undetermined pathogenesis is higher than the 1.9 per 100 patient&#x02010;years in patients with embolic stroke of unknown source reported by Perera et&#x000a0;al.<xref rid="jah310366-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> and possibly exceeds Nedeltchev and colleagues&#x02019;<xref rid="jah310366-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> reported 3% annual risk across all patients. Long&#x02010;term data from 396 young patients with stroke showed a 10.6% recurrence over a median follow&#x02010;up period of 11.8&#x02009;years.<xref rid="jah310366-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Notably, most patients who experienced recurrent strokes and were initially categorized under undetermined cause were later reclassified as large&#x02010;artery atherosclerosis, cardioembolism, small&#x02010;vessel occlusion, or other determined causes.<xref rid="jah310366-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> These findings, along with a 15% long&#x02010;term (&#x0003e;10&#x02009;years) AIS and transient ischemic attack recurrence rate in patients with embolic stroke of unknown source contrast the considerably lower 5.5% new incidence rate of atrial fibrillation and underscore the need for improved understanding of the pathophysiology of first&#x02010;ever and recurrent ischemic cerebrovascular events in these patients.<xref rid="jah310366-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> The discrepancy between functional outcomes and stroke recurrence rates in the undetermined pathogenesis group may seem unexpected. This observation could stem from inherent adverse prognostic factors in this group or more likely, the absence of a specific drug target for secondary prevention and the group's residual heterogeneity including undetected rare stroke causes.</p><p>Notably, 9.6% of patients had other identified causes, experiencing the highest rate of unfavorable outcomes (mRS score, 3&#x02013;6; 24%), short&#x02010;term stroke recurrence (3.4%), and death (3.4%), warranting further investigation of this heterogenous subgroup.</p><sec id="jah310366-sec-0023"><title>Strengths and Limitations</title><p>Strengths include (1) by using data from all Swiss stroke centers contributing to the prospective SSR (participation in the registry is mandatory for certification), a large, national, comprehensive sample was obtained, reducing potential selection bias; and (2) the comprehensive elucidation of several relevant aspects including functional outcomes, with previous studies having often focused on only partial aspects.</p><p>Limitations include (1) the lack of further information on pathogenetic diagnostic workup performed within the group with undetermined pathogenesis (such as laboratory thrombophilia screenings or rare inflammatory and autoimmune causes); (2) the use of the TOAST classification to categorize pathogeneses, which does not provide information on the certainty of the classification; (3) the limited generalizability of the results to other countries and regions with different demographics or health care infrastructure.</p></sec></sec><sec sec-type="conclusions" id="jah310366-sec-0024"><title>Conclusions</title><p>In adults aged 18&#x02013;55 with AIS, vascular risk factors were prevalent across all pathogeneses, including those with undetermined pathogenesis. Despite higher AIS recurrence rates in these patients, they exhibited more favorable functional outcomes, emphasizing the need for tailored prevention strategies and further research.</p></sec><sec id="jah310366-sec-0025"><title>Sources of Funding</title><p>The SSR was financially supported by the Swiss Heart Foundation (the funder). The funder had no influence on the study design, data collection, or data analysis.</p></sec><sec sec-type="COI-statement" id="jah310366-sec-0026"><title>Disclosures</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jah310366-supitem-0001" position="float" content-type="local-data"><caption><p>Swiss Stroke Registry: List of Collaborators</p><p>Data S1&#x02013;S3</p><p>Tables S1&#x02013;S14</p><p>Figures&#x000a0;S1&#x02013;S3</p></caption><media xlink:href="JAH3-13-e036761-s001.pdf"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah310366-bibl-0001"><title>REFERENCES</title><ref id="jah310366-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah310366-cit-0001">
<string-name>
<surname>Ekker</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Verhoeven</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Schellekens</surname>
<given-names>MMI</given-names>
</string-name>, <string-name>
<surname>Boot</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Van Alebeek</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Brouwers</surname>
<given-names>PJAM</given-names>
</string-name>, <string-name>
<surname>Arntz</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Van Dijk</surname>
<given-names>GW</given-names>
</string-name>, <string-name>
<surname>Gons</surname>
<given-names>RAR</given-names>
</string-name>, <string-name>
<surname>Van Uden</surname>
<given-names>IWM</given-names>
</string-name>, et&#x000a0;al. <article-title>Risk factors and causes of ischemic stroke in 1322 young adults</article-title>. <source>Stroke</source>. <year>2023</year>;<volume>54</volume>:<fpage>439</fpage>&#x02013;<lpage>447</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.122.040524</pub-id>
<pub-id pub-id-type="pmid">36511150</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah310366-cit-0002">
<string-name>
<surname>Ekker</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Verhoeven</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Vaartjes</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>van Nieuwenhuizen</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Klijn</surname>
<given-names>CJM</given-names>
</string-name>, <string-name>
<surname>de Leeuw</surname>
<given-names>FE</given-names>
</string-name>. <article-title>Stroke incidence in young adults according to age, subtype, sex, and time trends</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>:<fpage>e2444</fpage>&#x02013;<lpage>e2454</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.0000000000007533</pub-id>
<pub-id pub-id-type="pmid">31019103</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah310366-cit-0003">
<string-name>
<surname>Yannick</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Benoit</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Agn&#x000e8;s</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>J&#x000e9;r&#x000f4;me</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guy&#x02010;Victor</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Olivier</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Maurice</surname>
<given-names>G</given-names>
</string-name>. <article-title>Trends in the incidence of ischaemic stroke in young adults between 1985 and 2011: the Dijon stroke registry</article-title>. <source>J Neurol Neurosurg Psych</source>. <year>2014</year>;<volume>85</volume>:<fpage>509</fpage>&#x02013;<lpage>513</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2013-306203</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah310366-cit-0004">
<string-name>
<surname>George</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Tong</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Kuklina</surname>
<given-names>EV</given-names>
</string-name>, <string-name>
<surname>Labarthe</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995&#x02013;2008</article-title>. <source>Ann Neurol</source>. <year>2011</year>;<volume>70</volume>:<fpage>713</fpage>&#x02013;<lpage>721</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.22539</pub-id>
<pub-id pub-id-type="pmid">21898534</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah310366-cit-0005">
<string-name>
<surname>Fraser</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pabst</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>F</given-names>
</string-name>. <article-title>Stroke in the young</article-title>. <source>Curr Opin Neurol</source>. <year>2023</year>;<volume>36</volume>:<fpage>131</fpage>&#x02013;<lpage>139</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WCO.0000000000001145</pub-id>
<pub-id pub-id-type="pmid">36762634</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah310366-cit-0006">
<string-name>
<surname>Nedeltchev</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Maur</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Georgiadis</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caso</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mattle</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Schroth</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Remonda</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sturzenegger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>
<given-names>U</given-names>
</string-name>, et&#x000a0;al. <article-title>Ischaemic stroke in young adults: predictors of outcome and recurrence</article-title>. <source>J Neurol Neurosurg Psych</source>. <year>2005</year>;<volume>76</volume>:<fpage>191</fpage>&#x02013;<lpage>195</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.2004.040543</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah310366-cit-0007">
<string-name>
<surname>Goeggel Simonetti</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Mono</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Huynh&#x02010;Do</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Odier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Sztajzel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lyrer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Engelter</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Bonati</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gensicke</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Risk factors, apathogenesis and outcome of ischaemic stroke in young adults: the swiss young stroke study (SYSS)</article-title>. <source>J Neurol</source>. <year>2015</year>;<volume>262</volume>:<fpage>2025</fpage>&#x02013;<lpage>2032</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-015-7805-5</pub-id>
<pub-id pub-id-type="pmid">26067218</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah310366-cit-0008">
<string-name>
<surname>Rutten&#x02010;Jacobs</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Arntz</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Maaijwee</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Schoonderwaldt</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Dorresteijn</surname>
<given-names>LD</given-names>
</string-name>, <string-name>
<surname>van Dijk</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>de Leeuw</surname>
<given-names>FE</given-names>
</string-name>. <article-title>Long&#x02010;term mortality after stroke among adults aged 18 to 50&#x02009;years</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>309</volume>:<fpage>1136</fpage>&#x02013;<lpage>1144</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2013.842</pub-id>
<pub-id pub-id-type="pmid">23512060</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah310366-cit-0009">
<string-name>
<surname>Hauer</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ruigrok</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Algra</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dijk</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Koudstaal</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Luijckx</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Nederkoorn</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Oostenbrugge</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Visser</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wermer</surname>
<given-names>MJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Age&#x02010;specific vascular risk factor profiles according to stroke subtype</article-title>. <source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005090</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.116.005090</pub-id>
<pub-id pub-id-type="pmid">28483775</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah310366-cit-0010">
<string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Rothwell</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Association of Younger vs older ages with changes in incidence of stroke and other vascular events, 2002&#x02013;2018</article-title>. <source>Jama</source>. <year>2022</year>;<volume>328</volume>:<fpage>563</fpage>&#x02013;<lpage>574</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2022.12759</pub-id>
<pub-id pub-id-type="pmid">35943470</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah310366-cit-0011">
<string-name>
<surname>Nam</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Heo</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Long&#x02010;term mortality in patients with stroke of undetermined etiology</article-title>. <source>Stroke J Cerebral Circul</source>. <year>2012</year>;<volume>43</volume>:<fpage>2948</fpage>&#x02013;<lpage>2956</lpage>. doi: <pub-id pub-id-type="doi">10.1161/strokeaha.112.661074</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah310366-cit-0012">
<string-name>
<surname>Fine</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Gray</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source>. <year>1999</year>;<volume>94</volume>:<fpage>496</fpage>&#x02013;<lpage>509</lpage>. doi: <pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah310366-cit-0013">
<string-name>
<surname>von Elm</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Egger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pocock</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>Vandenbroucke</surname>
<given-names>JP</given-names>
</string-name>. <article-title>The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>J Clin Epidemiol</source>. <year>2008</year>;<volume>61</volume>:<fpage>344</fpage>&#x02013;<lpage>349</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.11.008</pub-id>
<pub-id pub-id-type="pmid">18313558</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah310366-cit-0014">
<string-name>
<surname>Putaala</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yesilot</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Waje&#x02010;Andreassen</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Pitk&#x000e4;niemi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vassilopoulou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nardi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Odier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hofg&#x000e1;rt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Engelter</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Burow</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Demographic and geographic vascular risk factor differences in European young adults with ischemic stroke</article-title>. <source>Stroke J Cerebral Circul</source>. <year>2012</year>;<volume>43</volume>:<fpage>2624</fpage>&#x02013;<lpage>2630</lpage>. doi: <pub-id pub-id-type="doi">10.1161/strokeaha.112.662866</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah310366-cit-0015">
<string-name>
<surname>Kim</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>C&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S&#x02010;Y</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>Y&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Bang</surname>
<given-names>OY</given-names>
</string-name>. <article-title>Association between the amount of right&#x02010;to&#x02010;left shunt and infarct patterns in patients with cryptogenic embolic stroke: a transcranial doppler study</article-title>. <source>Int J Stroke</source>. <year>2012</year>;<volume>8</volume>:<fpage>657</fpage>&#x02013;<lpage>662</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1747-4949.2012.00846.x</pub-id>
<pub-id pub-id-type="pmid">22812924</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah310366-cit-0016">
<string-name>
<surname>Homma</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tullio</surname>
<given-names>MRD</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Mihalatos</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mandri</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Mohr</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Characteristics of patent foramen Ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study</article-title>. <source>Stroke J Cerebral Circul</source>. <year>1994</year>;<volume>25</volume>:<fpage>582</fpage>&#x02013;<lpage>586</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.str.25.3.582</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah310366-cit-0017">
<string-name>
<surname>Allen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Frost</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liabo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pearn</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Monks</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Everson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>James</surname>
<given-names>M</given-names>
</string-name>. <article-title>Use of clinical pathway simulation and machine learning to identify key levers for maximizing the benefit of intravenous thrombolysis in acute stroke</article-title>. <source>Stroke J Cerebral Circul</source>. <year>2022</year>;<volume>53</volume>:<fpage>2758</fpage>&#x02013;<lpage>2767</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.121.038454</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah310366-cit-0018">
<string-name>
<surname>Anand</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Benjamin</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Adapa</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Daou</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Pandey</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Trends in acute ischemic stroke treatments and mortality in the United States from 2012 to 2018</article-title>. <source>Neurosurg Focus</source>. <year>2021</year>;<volume>51</volume>:<fpage>E2</fpage>. doi: <pub-id pub-id-type="doi">10.3171/2021.4.FOCUS21117</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah310366-cit-0019">
<string-name>
<surname>Norrving</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Barrick</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Davalos</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dichgans</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cordonnier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Guekht</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kutluk</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mikulik</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wardlaw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Richard</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Action plan for stroke in Europe 2018&#x02013;2030</article-title>. <source>Eur Stroke J</source>. <year>2018</year>;<volume>3</volume>:<fpage>309</fpage>&#x02013;<lpage>336</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2396987318808719</pub-id>
<pub-id pub-id-type="pmid">31236480</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah310366-cit-0020">
<string-name>
<surname>Hart</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mundl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kasner</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Bangdiwala</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Berkowitz</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Swaminathan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lavados</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Rivaroxaban for stroke prevention after embolic stroke of undetermined source</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>2191</fpage>&#x02013;<lpage>2201</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1802686</pub-id>
<pub-id pub-id-type="pmid">29766772</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah310366-cit-0021">
<string-name>
<surname>Diener</surname>
<given-names>H&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Bernstein</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Uchiyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kreuzer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cronin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cotton</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Grauer</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Dabigatran for prevention of stroke after embolic stroke of undetermined source</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>1906</fpage>&#x02013;<lpage>1917</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1813959</pub-id>
<pub-id pub-id-type="pmid">31091372</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah310366-cit-0022">
<string-name>
<surname>Perera</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>de Sa</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Rao&#x02010;Melacini</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fabregas</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Ameriso</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Field</surname>
<given-names>TS</given-names>
</string-name>, et&#x000a0;al. <article-title>Evaluating rates of recurrent ischemic stroke among young adults with embolic stroke of undetermined source: the young ESUS longitudinal cohort study</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>:<fpage>450</fpage>&#x02013;<lpage>458</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2022.0048</pub-id>
<pub-id pub-id-type="pmid">35285869</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah310366-cit-0023">
<string-name>
<surname>Broman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fandler&#x02010;H&#x000f6;fler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bv</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Elmegiri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gattringer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Holbe</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jvd</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Malinowski</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Martola</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pinter</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Long&#x02010;term risk of recurrent vascular events and mortality in young stroke patients: insights from a multicenter study</article-title>. <source>Eur J Neurol</source>. <year>2023</year>;<volume>30</volume>:<fpage>2675</fpage>&#x02013;<lpage>2683</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ene.15850</pub-id>
<pub-id pub-id-type="pmid">37159485</pub-id>
</mixed-citation></ref><ref id="jah310366-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah310366-cit-0024">
<string-name>
<surname>Nassif</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Annink</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Rettig</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Roos</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>van den Brink</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tijssen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mulder</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>de Winter</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bouma</surname>
<given-names>B</given-names>
</string-name>. <article-title>Long&#x02010;term (&#x0003e;10&#x02010;year) clinical follow&#x02010;up after young embolic stroke/TIA of undetermined source</article-title>. <source>Int J Stroke</source>. <year>2021</year>;<volume>16</volume>:<fpage>7</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1747493019884520</pub-id>
<pub-id pub-id-type="pmid">31679479</pub-id>
</mixed-citation></ref></ref-list></back></article>